0:000:00
<p>CAC 0 takes a gut punch, ICD therapies cannot be surrogates for benefit, and two important trials from ESC are the topics John Mandrola, MD, discusses in this week's podcast.</p> <p><em>This podcast is intended for healthcare professionals only</em>.</p> <p>To read a partial transcript or to comment, visit:</p> <p>https://www.medscape.com/twic</p> <p><strong>I CAC 0</strong></p> <ul> <li><strong>LDL-C and CVD Risk With CAC Score 0 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf497/8228645</strong></li> </ul> <p><strong>II ICD Therapies</strong></p> <ul> <li><strong>Contemporary ICD Benefit https://www.jacc.org/doi/10.1016/j.jacep.2025.06.028</strong></li> <li><strong>PROFID Trial https://profid-project.eu/profid-ehra-trial/</strong></li> <li><strong>MADIT-RIT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1211107</strong></li> <li><strong>Declining Risk of Sudden Death in HF https://www.nejm.org/doi/full/10.1056/NEJMoa1609758</strong></li> </ul> <p><...